RX ITEM-Increlex 10Mg/Ml Vial 10X4Ml By Tercica

INCRELEX- mecasermin injection, solution
Ipsen Biopharmaceuticals, Inc.

1 INDICATIONS AND USAGE

1.1 Severe Primary IGF-1 Deficiency (Primary IGFD)
INCRELEX� (mecasermin [rDNA origin] injection) is indicated for the treatment of:

growth failure in children with severe primary IGF-1 deficiency.
growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
Severe Primary IGF-1 deficiency (IGFD) is defined by:

height standard deviation score ? �3.0 and
basal IGF-1 standard deviation score ? �3.0 and
normal or elevated growth hormone (GH).


Severe Primary IGFD includes classical and other forms of growth hormone insensitivity. Patients with Primary IGFD may have mutations in the GH receptor (GHR), post-GHR signaling pathway including the IGF-1 gene. They are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment.

INCRELEX� is not intended for use in subjects with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids. Thyroid and nutritional deficiencies should be corrected before initiating INCRELEX� treatment.

Limitations of use: INCRELEX� is not a substitute to GH for approved GH indications.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage
Preprandial glucose monitoring is recommended at treatment initiation and until a well-tolerated dose is established. If frequent symptoms of hypoglycemia or severe hypoglycemia occur, preprandial glucose monitoring should continue. The dosage of INCRELEX� should be individualized for each patient. The recommended starting dose of INCRELEX� is 0.04 to 0.08 mg/kg (40 to 80 micrograms/kg) twice daily by subcutaneous injection. If well-tolerated for at least one week, the dose may be increased by 0.04 mg/kg per dose, to the maximum dose of 0.12 mg/kg given twice daily. Doses greater than 0.12 mg/kg given twice daily have not been evaluated in children with Primary IGFD and, due to potential hypoglycemic effects, should not be used. If hypoglycemia occurs with recommended doses despite adequate food intake, the dose should be reduced. INCRELEX� should be administered shortly before or after (� 20 minutes) a meal or snack. If the patient is unable to eat shortly before or after a dose for any reason, that dose of INCRELEX� should be withheld. Subsequent doses of INCRELEX� should never be increased to make up for one or more omitted doses.

Treatment with INCRELEX should be supervised by a physician who is experienced in the diagnosis and management of pediatric patients with short stature associated with severe primary IGF-1 deficiency or with growth hormone gene deletion and who have developed neutralizing antibodies to growth hormone.

RX ITEM-Increlex 10Mg/Ml Vial 10X4Ml By
NDC 15054-1040-05 UPC/GTIN No.3-15054-10405-6 Mfg.Part No.15054-1040-05

Increlex 10Mg/Ml Vial 10X4Ml By Tercica
BRAND: INCRELEX NDC: 15054-1040-05,15054104005 UPC: 3-15054-10405-6,315054104056 Tercica, Inc.

MECASERMIN SUB-Q VIAL 10
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.